Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAEST16001 in NY-ESO-1 Positive Solid Tumors
NCT04318964Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAEST16001 in soft tissue sarcoma (STS) and solid tumor, sponsored by Sun Yat-sen University. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
TAEST16001
03
Conditions
soft tissue sarcoma (STS)solid tumor
Beyond the preview
Go deeper on NCT04318964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318964.